Zev M Nakamura1, Allison M Deal2, Kirsten A Nyrop2,3, Seul Ki Choi4, William A Wood2,3, Hyman B Muss2,3. 1. Department of Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 2. Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. Department of Medicine, Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 4. Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Abstract
OBJECTIVE: To describe associations of functional, psychosocial, medical, and socio-demographic factors with performance on a cognitive screening test in chemotherapy naïve patients with breast cancer. METHODS: Women with breast cancer were recruited between 2009 and 2018. The Blessed Orientation Memory Concentration Test (BOMC) was administered prior to chemotherapy. Associations between baseline BOMC and functional (Karnofsky Self-Reported Performance Rating Scale (KPS), Time Up and Go Test (TUG), Medical Outcomes Study (MOS) Physical Function, Instrumental Activities of Daily Living (IADL)), psychosocial (Mental Health Inventory-13, MOS Social Activity Limitation and Social Support Survey), medical, and socio-demographic variables were assessed using linear regression analysis. RESULTS: In a sample of 331 women with breast cancer, the mean age was 65.2 years and 68.6% were 65 and older. Mean BOMC score was 3.60 on a scale from 0 (best) to 28 (worst). After controlling for demographic factors, worse BOMC screening test results were associated with KPS < 80 (P = 0.01), IADL<14 (P = 0.02), TUG ≥14 seconds (P = 0.001), worse MOS Physical Function (P = 0.0006), depressive symptoms (P = 0.04), and social activity limitations (P = 0.01). CONCLUSION: In a sample of women with breast cancer, pre-treatment cognitive screening scores did not reveal profound cognitive impairment. BOMC screening scores were associated with multiple measures of physical function, but further research is needed to determine a clinically meaningful cut point in the BOMC for screening of cancer-related cognitive impairment.
OBJECTIVE: To describe associations of functional, psychosocial, medical, and socio-demographic factors with performance on a cognitive screening test in chemotherapy naïve patients with breast cancer. METHODS:Women with breast cancer were recruited between 2009 and 2018. The Blessed Orientation Memory Concentration Test (BOMC) was administered prior to chemotherapy. Associations between baseline BOMC and functional (Karnofsky Self-Reported Performance Rating Scale (KPS), Time Up and Go Test (TUG), Medical Outcomes Study (MOS) Physical Function, Instrumental Activities of Daily Living (IADL)), psychosocial (Mental Health Inventory-13, MOS Social Activity Limitation and Social Support Survey), medical, and socio-demographic variables were assessed using linear regression analysis. RESULTS: In a sample of 331 women with breast cancer, the mean age was 65.2 years and 68.6% were 65 and older. Mean BOMC score was 3.60 on a scale from 0 (best) to 28 (worst). After controlling for demographic factors, worse BOMC screening test results were associated with KPS < 80 (P = 0.01), IADL<14 (P = 0.02), TUG ≥14 seconds (P = 0.001), worse MOS Physical Function (P = 0.0006), depressive symptoms (P = 0.04), and social activity limitations (P = 0.01). CONCLUSION: In a sample of women with breast cancer, pre-treatment cognitive screening scores did not reveal profound cognitive impairment. BOMC screening scores were associated with multiple measures of physical function, but further research is needed to determine a clinically meaningful cut point in the BOMC for screening of cancer-related cognitive impairment.
Authors: Yu-Yin Allemann-Su; Marcus Vetter; Helen Koechlin; Steven M Paul; Bruce A Cooper; Kate Oppegaard; Michelle Melisko; Jon D Levine; Yvette Conley; Christine Miaskowski; Maria C Katapodi Journal: Cancers (Basel) Date: 2022-07-05 Impact factor: 6.575
Authors: Reena V Jayani; Allison M Magnuson; Can-Lan Sun; Huiyan Ma; William P Tew; Supriya G Mohile; Ajeet Gajra; Heidi D Klepin; Cary P Gross; Hyman B Muss; Andrew E Chapman; Vani Katheria; Arti Hurria; William Dale Journal: J Geriatr Oncol Date: 2019-12-06 Impact factor: 3.599
Authors: Sheri J Hartman; Lauren S Weiner; Sandahl H Nelson; Loki Natarajan; Ruth E Patterson; Barton W Palmer; Barbara A Parker; Dorothy D Sears Journal: JMIR Cancer Date: 2019-10-11